Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook for Compass Pathways PLC is supported by a 95% probability of success for its proprietary COMP360 psilocybin therapy, bolstered by favorable regulatory trends and positive clinical trial results. The recent data from the COMP005 study demonstrates a statistically significant -3.6-point placebo-adjusted reduction on the MADRS scale, which highlights the potential efficacy of COMP360 in treating treatment-resistant depression (TRD). Furthermore, the anticipated low-frequency dosing of COMP360, requiring only 2–4 sessions annually compared to existing therapies, positions the company advantageously within the competitive landscape of mental health treatments.

Bears say

Compass Pathways PLC is currently facing a challenging financial landscape, underscored by its substantial cash burn due to higher-than-expected research and development expenses for the COMP360 Phase 3 clinical trials, resulting in a decrease in cash reserves to $221.9 million as of June 30. Additionally, the company may encounter competitive pressures if rivals produce compelling data in the mental health treatment space, which could adversely affect its stock performance. Furthermore, a lowered discount rate of 18.5% indicates diminishing expectations regarding the successful rollout of COMP360 amidst a burgeoning ketamine treatment market, highlighting further strategic and financial vulnerabilities for the firm.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.